ArticleAnnals of the American Thoracic Society2020
Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry.
Article in Annals of the American Thoracic Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk.Scientific reports · 2026Article
- PLK1 inhibition by volasertib suppresses key transcriptional regulators underlying fibroblast activation and pulmonary fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2026Article
- The benefits of a rapid diagnostic primary care circuit for interstitial lung disease.NPJ primary care respiratory medicine · 2025Article
- Caring for Rural Patients With Interstitial Lung Disease: Perspectives of Pulmonary Fibrosis Foundation Care Center Network Nurses and Providers.CHEST pulmonary · 2025Article
- Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study.BMC pulmonary medicine · 2025Article
- Cost-effectiveness of novel diagnostic tools for idiopathic pulmonary fibrosis in the United States.BMC health services research · 2025Article
- Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry.BMJ open respiratory research · 2025Observational
- Progressive Early Interstitial Lung Abnormalities in Persons at Risk for Familial Pulmonary Fibrosis: A Prospective Cohort Study.American journal of respiratory and critical care medicine · 2024Article
- The prognostic role of high-density lipoprotein cholesterol/C-reactive protein ratio in idiopathic pulmonary fibrosis.QJM : monthly journal of the Association of Physicians · 2024Observational
- The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.Respiratory research · 2024Article
- Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies.Biomedicines · 2024Review
- Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016-2022.Annals of the American Thoracic Society · 2024Article
- A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib.Scientific reports · 2023Article
- Induced pluripotent stem cells modulate the Wnt pathway in the bleomycin-induced model of idiopathic pulmonary fibrosis.Stem cell research & therapy · 2023Article
- Overall drug treatment of idiopathic pulmonary fibrosis patients from national registries - a real-world study from Finland.BMC pulmonary medicine · 2023Article
- The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).PharmacoEconomics · 2023Observational
- Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis.Chest · 2023Article
- Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review.Pulmonary therapy · 2023Review
- Observational
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.